Daily Endocrinology Research Analysis
Analyzed 186 papers and selected 3 impactful papers.
Summary
Today’s most impactful endocrinology-related papers span a newly identified pulmonary-to-adipose thermogenic pathway, a randomized clinical trial of topical antimicrobial peptide therapy for infected diabetic foot ulcers, and a large registry-based study revealing the severe systemic prognosis of Charcot neuro-osteoarthropathy. Together, these studies connect mechanistic innovation with clinically actionable treatment and risk-stratification evidence.
Research Themes
- Pulmonary cold sensing and adipose thermogenesis
- Novel antimicrobial therapy for infected diabetic foot ulcers
- Systemic prognosis and multidisciplinary management of Charcot neuro-osteoarthropathy
Selected Articles
1. Pulmonary cold sensing through Club cells triggers adipose thermogenesis to ameliorate obesity.
This study identifies a previously unrecognized peripheral thermoregulatory circuit in which bronchial Club cells sense cold through KCNK2 channels. Cold-induced calcium signaling increases Irisin expression and secretion, activating adipose thermogenesis; pharmacological stimulation of the pathway reduced obesity in mice.
Impact: The work establishes the lung as an active metabolic sensor rather than merely a passive organ exposed to environmental temperature. It provides a mechanistically novel, potentially targetable pulmonary–adipose axis for obesity treatment.
Clinical Implications: The findings are preclinical and do not yet justify pulmonary drug delivery or KCNK2-targeted therapy in humans. They support development of tissue-selective strategies to activate thermogenesis while minimizing systemic adverse effects.
Key Findings
- KCNK2 channels in bronchial Club cells function as pulmonary cold sensors.
- Cold-induced calcium fluctuations increase Irisin expression and secretion, promoting adipose thermogenesis.
- Pharmacological activation of the pathway through tracheal fluoxetine delivery enhanced thermogenesis and ameliorated obesity in mice.
Methodological Strengths
- Use of complementary genetic and adeno-associated virus-based mouse models to interrogate the pulmonary pathway.
- Integration of cellular signaling, endocrine communication, thermogenic physiology, and an obesity phenotype.
Limitations
- The evidence is based on mouse models, and conservation of the pathway in humans remains unestablished.
- The safety, selectivity, dose, and long-term effects of pulmonary pharmacological activation were not determined.
Future Directions: Future studies should confirm KCNK2–Irisin signaling in human airway tissue, define the relevant neural and endocrine connections, and evaluate selective inhaled or airway-directed therapies in translational models.
Cold exposure is a well-known trigger for thermogenesis, primarily through skin cold-sensitive neurons activating adipose metabolism via the central nervous system (CNS). However, whether the lungs-also exposed to cold air-function as a cold sensor and regulate metabolism remains unknown. Here, using CC10-Cre- and adeno-associated virus (AAV)-based mouse models, we uncover a pulmonary cold sensing system that drives thermogenesis, establishing a peripheral thermoregulatory mechanism. Specifically, we identify KCNK2 channels in Club cells within the bronchial epithelium as primary pulmonary cold sensors, where cold exposure enhances Irisin expression and secretion via Ca²⁺ fluctuations to drive thermogenesis in adipose tissue. Notably, pharmacological activation of this pathway via fluoxetine tracheal infusion enhances thermogenesis and ameliorates obesity in mice, highlighting a potential anti-obesity delivery strategy.
2. Effect of Topical Application of Antimicrobial Peptide PL-5 (Peceleganan) Spray on Mild to Moderate Infection of Diabetic Foot Ulcers: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
In this multicenter randomized double-blind trial, PL-5 spray plus standardized debridement improved the short-term clinical response rate compared with placebo. The benefit was particularly evident for clearance of drug-resistant bacteria, while overall microbiological eradication was not significantly different and safety was comparable.
Impact: This is clinically relevant randomized evidence for a topical, potentially low-resistance therapy in diabetic foot infection, an area threatened by antimicrobial resistance. The selective effect against drug-resistant organisms is particularly important for limb-preserving care.
Clinical Implications: PL-5 may become an adjunct to debridement for mild-to-moderate infected diabetic foot ulcers, particularly when drug-resistant bacteria are present. It should not replace systemic antibiotics or standard infection assessment until larger trials establish effects on healing, recurrence, hospitalization, and amputation.
Key Findings
- PL-5 produced a significantly higher clinical response rate at one day after treatment completion than placebo.
- Drug-resistant bacterial clearance was 71.43% with PL-5 versus 50% with placebo.
- Overall microbiological eradication did not differ significantly at treatment completion or seven days later, and no serious drug-related adverse events were observed.
Methodological Strengths
- Multicenter randomized, double-blind, placebo-controlled clinical design with standardized debridement in both groups.
- Assessment of both clinical response and microbiological outcomes, including drug-resistant organisms.
Limitations
- The participant number and detailed effect estimates are not reported in the provided abstract.
- Follow-up was short, and overall microbiological eradication was not significantly improved.
Future Directions: Larger adequately powered trials should evaluate complete wound healing, time to healing, recurrence, hospitalization, amputation, quality of life, resistance emergence, and outcomes stratified by pathogen and ulcer severity.
AIMS: To evaluate the clinical efficacy and safety of topical antimicrobial peptide PL-5 (Peceleganan) spray combined with standard debridement in the treatment of mildly to moderately infected diabetic foot ulcers (DFUs). MATERIALS AND METHODS: This multicenter, randomized, double-blind, placebo-controlled trial was conducted in four tertiary hospitals. Eligible patients were randomized to PL-5 spray or placebo, both receiving standardized debridement. The primary endpoint was clinical response rate at 1 day after end of treatment (EOT1). RESULTS: Baseline characteristics were balanced between groups. The clinical response rate at EOT1 was significantly higher in the PL-5 group than in the placebo group (p < 0.05). The clearance rate of drug-resistant bacteria at EOT1 was 71.43% in the PL-5 group versus 50% in the control group (p < 0.05). No significant differences were observed in overall microbiological eradication rates at EOT1 (57.89% vs. 33.33%) or EOT7 (64.71% vs. 40.00%) (both p > 0.05).
3. Emergency Hospitalization, Amputation, and Survival After Charcot Neuro-Osteoarthropathy Diagnosis in People With Diabetes: A Regional Registry-Based Cohort Study.
Among 127,513 adults with diabetes, only 140 had a recorded first diagnosis of Charcot neuro-osteoarthropathy, but their subsequent outcomes were severe: 87.9% experienced emergency hospitalization, 31.4% underwent lower-extremity amputation, and 37.9% died over a median 4.6 years. Advanced chronic kidney disease and high or active foot-risk status identified patients at particularly high risk.
Impact: The study quantifies the substantial systemic vulnerability associated with Charcot neuro-osteoarthropathy using routinely collected health-care data. It supports treating CNO as a medical emergency and a marker for intensified multidisciplinary surveillance rather than an isolated foot complication.
Clinical Implications: A new CNO diagnosis should trigger urgent multidisciplinary management involving diabetology, podiatry, orthopedics, vascular care, renal medicine, wound care, and rehabilitation. Patients with advanced chronic kidney disease or high foot-risk status may require especially intensive follow-up and early preventive intervention.
Key Findings
- Among 140 patients with newly recorded CNO, 87.9% experienced emergency hospitalization during a median 4.6-year follow-up.
- Lower-extremity amputation occurred in 31.4% and death in 37.9%; five-year amputation-free survival was 44%.
- Advanced chronic kidney disease was associated with higher risk across outcomes, while high or active foot-risk status strongly predicted amputation and shorter amputation-free survival.
Methodological Strengths
- Registry linkage captured real-world emergency hospitalization, amputation, mortality, and time-to-event outcomes over a median 4.6 years.
- Multivariable regression assessed clinical risk factors, including chronic kidney disease and foot-risk status.
Limitations
- Only 140 CNO cases were identified, limiting precision for subgroup analyses and rare outcomes.
- The study was regional and registry-based, so diagnostic misclassification, residual confounding, and limited generalizability are possible.
Future Directions: Prospective multicenter studies should test whether rapid off-loading, standardized CNO pathways, renal-risk stratification, and coordinated multidisciplinary surveillance reduce amputation, hospitalization, and mortality.
OBJECTIVE: The aim for this study was to describe adverse outcomes after Charcot neuro-osteoarthropathy (CNO) diagnosis in adults with diabetes and examine variation by clinical and sociodemographic characteristics. RESEARCH DESIGN AND METHODS: A regional, registry-based cohort study was conducted using linked routinely collected health care data from adults with diabetes and a first recorded CNO diagnosis in the National Health Service Greater Glasgow and Clyde, Scotland (2015-2024). Outcomes were all-cause emergency hospitalization, lower-extremity amputation, all-cause mortality, and amputation-free survival. Time-to-event methods and multivariable regression were used to estimate event probabilities and tested associations with clinical characteristics. RESULTS: From 127,513 adults with diabetes, 140 individuals with a first recorded CNO diagnosis were identified; their mean age was 59 years, and 67% were men. During a median 4.6-year follow-up, 123 patients (87.9%) had an emergency admission, 44 (31.4%) underwent lower-extremity amputation (minor or major), and 53 (37.9%) died.